Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.

Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM.

Eur J Cancer. 2018 Oct 22;104:160-168. doi: 10.1016/j.ejca.2018.09.003. [Epub ahead of print]

PMID:
30359909
2.

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.

3.

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH.

Eur J Cancer. 2018 Oct 8;104:21-31. doi: 10.1016/j.ejca.2018.08.011. [Epub ahead of print]

PMID:
30308388
4.

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC.

Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11.

PMID:
30206110
5.

Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S.

Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25.

PMID:
30053671
6.

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.

Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS.

J Natl Cancer Inst. 2018 Jul 18. doi: 10.1093/jnci/djy109. [Epub ahead of print]

PMID:
30032196
7.

Turgor maintenance by osmotic adjustment: 40 years of progress.

Turner NC.

J Exp Bot. 2018 Jun 6;69(13):3223-3233. doi: 10.1093/jxb/ery181.

PMID:
29767758
8.

Assessing HER2 Amplification in Plasma cfDNA.

Garcia-Murillas I, Turner NC.

Methods Mol Biol. 2018;1768:161-172. doi: 10.1007/978-1-4939-7778-9_10.

PMID:
29717443
9.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.

PMID:
29504847
10.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5.

PMID:
29504834
11.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC.

Nat Commun. 2018 Mar 1;9(1):896. doi: 10.1038/s41467-018-03215-x.

12.

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA.

Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797.

13.

Signatures of DNA-Repair Deficiencies in Breast Cancer.

Turner NC.

N Engl J Med. 2017 Dec 21;377(25):2490-2492. doi: 10.1056/NEJMcibr1710161. No abstract available.

PMID:
29262283
14.

Genotypic Variation in Yield, Yield Components, Root Morphology and Architecture, in Soybean in Relation to Water and Phosphorus Supply.

He J, Jin Y, Du YL, Wang T, Turner NC, Yang RP, Siddique KHM, Li FM.

Front Plant Sci. 2017 Aug 29;8:1499. doi: 10.3389/fpls.2017.01499. eCollection 2017.

15.

Seed germination of Caragana species from different regions is strongly driven by environmental cues and not phylogenetic signals.

Fang XW, Zhang JJ, Xu DH, Pang J, Gao TP, Zhang CH, Li FM, Turner NC.

Sci Rep. 2017 Sep 12;7(1):11248. doi: 10.1038/s41598-017-11294-x.

16.

Pattern of Water Use and Seed Yield under Terminal Drought in Chickpea Genotypes.

Pang J, Turner NC, Du YL, Colmer TD, Siddique KHM.

Front Plant Sci. 2017 Aug 9;8:1375. doi: 10.3389/fpls.2017.01375. eCollection 2017.

17.

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC.

Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.

18.

Drought-Tolerant Brassica rapa Shows Rapid Expression of Gene Networks for General Stress Responses and Programmed Cell Death Under Simulated Drought Stress.

Guo YM, Samans B, Chen S, Kibret KB, Hatzig S, Turner NC, Nelson MN, Cowling WA, Snowdon RJ.

Plant Mol Biol Report. 2017;35(4):416-430. doi: 10.1007/s11105-017-1032-4. Epub 2017 May 22.

19.

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkerd E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M.

Oncologist. 2017 Sep;22(9):1028-1038. doi: 10.1634/theoncologist.2017-0072. Epub 2017 Jun 26.

20.

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.

Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.

21.

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.

Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, Pearson A, Herrera-Abreu MT, Bakal C, Turner NC.

Clin Cancer Res. 2017 Sep 15;23(18):5561-5572. doi: 10.1158/1078-0432.CCR-17-0369. Epub 2017 Jun 12.

22.

Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.

Chopra N, Turner NC.

Lancet Oncol. 2017 Jul;18(7):842-843. doi: 10.1016/S1470-2045(17)30430-8. Epub 2017 May 30. No abstract available.

PMID:
28576676
23.

Advances and challenges in targeting FGFR signalling in cancer.

Babina IS, Turner NC.

Nat Rev Cancer. 2017 May;17(5):318-332. doi: 10.1038/nrc.2017.8. Epub 2017 Mar 17. Review.

PMID:
28303906
24.

Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.

Smyth EC, Babina IS, Turner NC.

Cancer Discov. 2017 Mar;7(3):248-249. doi: 10.1158/2159-8290.CD-17-0057.

25.

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.

Turner NC, Neven P, Loibl S, Andre F.

Lancet. 2017 Jun 17;389(10087):2403-2414. doi: 10.1016/S0140-6736(16)32419-9. Epub 2016 Dec 7. Review.

PMID:
27939057
26.

Apparent Overinvestment in Leaf Venation Relaxes Leaf Morphological Constraints on Photosynthesis in Arid Habitats.

de Boer HJ, Drake PL, Wendt E, Price CA, Schulze ED, Turner NC, Nicolle D, Veneklaas EJ.

Plant Physiol. 2016 Dec;172(4):2286-2299. Epub 2016 Oct 26.

27.

Turgor maintenance by osmotic adjustment, an adaptive mechanism for coping with plant water deficits.

Turner NC.

Plant Cell Environ. 2017 Jan;40(1):1-3. doi: 10.1111/pce.12839. Epub 2016 Nov 16. No abstract available.

PMID:
27723951
28.

Science in Focus: Circulating Tumour DNA as a Liquid Biopsy.

O'Leary B, Turner NC.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):735-738. doi: 10.1016/j.clon.2016.08.007. Epub 2016 Oct 4. No abstract available.

PMID:
27717550
29.

CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.

Lim JS, Turner NC, Yap TA.

Cancer Discov. 2016 Jul;6(7):697-9. doi: 10.1158/2159-8290.CD-16-0563.

30.

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).

Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS.

Oncologist. 2016 Oct;21(10):1165-1175. Epub 2016 Jul 1.

31.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC.

J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.

PMID:
27269946
32.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SRD, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC.

Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13.

33.

Response of chickpea (Cicer arietinum L.) to terminal drought: leaf stomatal conductance, pod abscisic acid concentration, and seed set.

Pang J, Turner NC, Khan T, Du YL, Xiong JL, Colmer TD, Devilla R, Stefanova K, Siddique KHM.

J Exp Bot. 2017 Apr 1;68(8):1973-1985. doi: 10.1093/jxb/erw153.

34.

Treating cancer with selective CDK4/6 inhibitors.

O'Leary B, Finn RS, Turner NC.

Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. Review.

PMID:
27030077
35.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V.

Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Erratum in: Cancer Res. 2016 Oct 1;76(19):5907.

36.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D.

Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3. Erratum in: Lancet Oncol. 2016 Apr;17 (4):e136. Lancet Oncol. 2016 Jul;17 (7):e270.

PMID:
26947331
37.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

38.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Turner NC, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2015 Oct 22;373(17):1672-3. doi: 10.1056/NEJMc1510345. No abstract available.

39.

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.

Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, Kozarewa I, Gonzalez de Castro D, Bhosle J, O'Brien M, Turner NC, Popat S, Downward J.

PLoS One. 2015 Sep 28;10(9):e0139074. doi: 10.1371/journal.pone.0139074. eCollection 2015.

40.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728
41.

Cutting improves the productivity of lucerne-rich stands used in the revegetation of degraded arable land in a semi-arid environment.

Yuan ZQ, Yu KL, Wang BX, Zhang WY, Zhang XL, Siddique KH, Stefanova K, Turner NC, Li FM.

Sci Rep. 2015 Jul 13;5:12130. doi: 10.1038/srep12130.

42.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group.

N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.

43.

Genotypic Variation in the Concentration of β-N-Oxalyl-L-α,β-diaminopropionic Acid (β-ODAP) in Grass Pea (Lathyrus sativus L.) Seeds Is Associated with an Accumulation of Leaf and Pod β-ODAP during Vegetative and Reproductive Stages at Three Levels of Water Stress.

Xiong JL, Xiong YC, Bai X, Kong HY, Tan RY, Zhu H, Siddique KH, Wang JY, Turner NC.

J Agric Food Chem. 2015 Jul 15;63(27):6133-41. doi: 10.1021/acs.jafc.5b01729. Epub 2015 Jun 29.

PMID:
26027639
44.

Two key genomic regions harbour QTLs for salinity tolerance in ICCV 2 × JG 11 derived chickpea (Cicer arietinum L.) recombinant inbred lines.

Pushpavalli R, Krishnamurthy L, Thudi M, Gaur PM, Rao MV, Siddique KH, Colmer TD, Turner NC, Varshney RK, Vadez V.

BMC Plant Biol. 2015 May 22;15:124. doi: 10.1186/s12870-015-0491-8.

45.

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC.

Mol Cancer Ther. 2015 Apr;14(4):865-76. doi: 10.1158/1535-7163.MCT-14-0845. Epub 2015 Feb 11.

46.

The history and future of targeting cyclin-dependent kinases in cancer therapy.

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES.

Nat Rev Drug Discov. 2015 Feb;14(2):130-46. doi: 10.1038/nrd4504. Review.

47.

Salt sensitivity in chickpea (Cicer arietinum L.): ions in reproductive tissues and yield components in contrasting genotypes.

Kotula L, Khan HA, Quealy J, Turner NC, Vadez V, Siddique KH, Clode PL, Colmer TD.

Plant Cell Environ. 2015 Aug;38(8):1565-77. doi: 10.1111/pce.12506. Epub 2015 Mar 4.

48.

Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours.

Litchfield K, Summersgill B, Yost S, Sultana R, Labreche K, Dudakia D, Renwick A, Seal S, Al-Saadi R, Broderick P, Turner NC, Houlston RS, Huddart R, Shipley J, Turnbull C.

Nat Commun. 2015 Jan 22;6:5973. doi: 10.1038/ncomms6973.

49.

Preface: two decades of InterDrought conferences: are we bridging the genotype-to-phenotype gap?

Tuberosa R, Turner NC, Cakir M.

J Exp Bot. 2014 Nov;65(21):6137-9. No abstract available.

PMID:
25544976
50.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

López-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I, Martin LA, Dowsett M.

Breast Cancer Res. 2014 Jun 30;16(3):R68. doi: 10.1186/bcr3683.

Supplemental Content

Loading ...
Support Center